

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A medical composition, comprising:

a peptide-capable of being labeled with a metal and

a basic organic compound acceptable as a pharmaceutical additive wherein the basic organic compound is a basic amino acid or a basic compound having an imidazole ring, wherein the peptide-capable of being labeled with a metal is a compound represented by chemical formula (1):



wherein in formula (1),

Z represents a protecting group for an amino group;

Y represents Met or Nle;

in (X)_n, X represents a spacer consisting of one or more amino acids or a compound capable of being organically synthesized, and n represents 1 or 0;

in (NH₂)_m, NH₂ represents an amide group serving as a protecting group for an α-carboxyl group of Lys, and m represents 1 or 0; and

in ε-(R)_o-(T)_l-U), R represents Ser or Thr bound via amide bond with an ε-amino group of Lys,

o represents 1 or 0;

~~T represents a spacer consisting of one or more amino acids or a compound capable of being organically synthesized, I represents 1 or 0, and U represents a group capable of being labeled with a metal,~~

~~provided that X and T may be identical or different selected from the group consisting of N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH₂)-ε(-Ser-Cys-Gly-Asn) (SEQ ID NO:1), N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH₂)-ε(-Ser-Cys-Gly-Asp) (SEQ ID NO:2), N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys-ε(-Ser-Cys-Asp-Asp) (SEQ ID NO:3), N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH₂)-ε(-Ser-D-Arg-Asp-Cys-Asp-Asp) (SEQ ID NO:4), N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys(NH₂)-ε(-Ser-D-Arg-diethylenetriaminepentaacetic acid (DTPA)) (SEQ ID NO:5), N-formyl-Met-Leu-Phe-Lys-ε(-Asp-Asp-mercaptoacetyl) (SEQ ID NO:7), N-formyl-Met-Leu-Phe-Lys-ε(-Gly-Asp-mercaptoacetyl) (SEQ ID NO:8), and N-formyl-Met-Leu-Phe-Lys-ε(-Gly-Gly-mercaptoacetyl) (SEQ ID NO:9).~~

2-3. (canceled).

4. (previously presented): The medical composition according to claim 1, wherein the basic amino acid is one or more members selected from arginine, histidine, and lysine.

5. (previously presented): The medical composition according to claim 1, wherein the basic compound having an imidazole ring is imidazole.

6. **(currently amended):** The medical composition according to claim 1, wherein
the peptide-capable of being labeled with a metal is a peptide available as an active ingredient in
a diagnostic drug or a pharmaceutical drug for therapeutic use.

7. **(currently amended):** The medical composition according to claim 1, wherein
the peptide-capable of being labeled with a metal has 30 or less amino acid residues or a
molecular weight of 4500 or less.

8. **(currently amended):** The medical composition according to claim 1, wherein
the peptide-capable of being labeled with a metal is a leukocyte-binding compound.

9. **(canceled).**

10. **(canceled).**

11. **(canceled).**

12. **(canceled).**

13. **(canceled).**

14. (previously presented): The medical composition according to claim 1, wherein the composition further comprises one or more additives selected from a reductant, pH adjuster, surfactant, hydrophilic organic solvent, and stabilizer.

15. (previously presented): A freeze-dried medical composition characterized in that the composition is obtained by freeze-drying a medical composition according to claim 1.

16. (currently amended): A medical preparation characterized in that the preparation is obtained by labeling, with a metal, a peptide ~~capable of being~~ labeled with a metal in a medical composition according to claim 1.

17. (original): The medical preparation according to claim 16, wherein the metal is a radioactive metal or paramagnetic metal.

18. (original): The medical preparation according to claim 17, wherein the radioactive metal is selected from Tc-99m, In-111, Ga-67, Y-90, Sn-117m, Sm-153, Re-186, and Re-188.

19. (original): The medical preparation according to claim 17, wherein the paramagnetic metal is selected from Gd, Fe, Mn, Cu, and Dy.

20. (withdrawn—currently amended): A method for labeling, with a metal, a peptide ~~capable of being~~ labeled with a metal, comprising the steps of:

dissolving the peptide in an aqueous solvent of a basic organic compound; and then labeling the resulting product with a metal.

21. (withdrawn—currently amended): The metal-labeling method according to claim 20, wherein the peptide ~~capable of being~~ labeled with a metal is a peptide insoluble or poorly soluble in an aqueous solvent.

22. (withdrawn): The metal-labeling method according to claim 20, wherein the basic organic compound is a basic amino acid or a basic compound having an imidazole ring.

23. (withdrawn): The metal-labeling method according to claim 22, characterized in that the basic amino acid is one or more members selected from arginine, histidine, and lysine.

24. (withdrawn): The metal-labeling method according to claim 22, wherein the basic compound having an imidazole ring is imidazole.

25. (withdrawn): The metal-labeling method according to claim 20, characterized in that the metal is a radioactive metal or paramagnetic metal.

26. (withdrawn): The metal-labeling method according to claim 25, wherein the radioactive metal is selected from Tc-99m, In-111, Ga-67, Y-90, Sn-117m, Sm-153, Re-186, and Re-188.

27. (withdrawn): The metal-labeling method according to claim 25, wherein the paramagnetic metal is selected from Gd, Fe, Mn, Cu, and Dy.

28. (withdrawn): A method for producing a medical preparation comprising a metal-labeled peptide, characterized by using a metal-labeling method according to claim 20.